Biotech IPO bonanza: Legend's $350M offering as Repare, Forma get in on the action

Legend Biotech is living up to its name as it sets terms for a massive $350 million IPO, while early-stage cancer biotech Repare Therapeutics and blood-disease-focused Forma Therapeutics also look to go public.

First up is Chinese CAR-T player Legend Biotech, which is being spun out of Genscript Biotech and has set terms for a $350 million IPO, gunning for a market value of around $2.6 billion.